News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
652,998 Results
Type
Article (59267)
Company Profile (209)
Press Release (593522)
Section
Business (181178)
Career Advice (3045)
Deals (32881)
Drug Delivery (105)
Drug Development (83020)
Employer Resources (170)
FDA (16675)
Job Trends (14914)
News (323876)
Policy (35128)
Tag
Academia (2867)
Africa (963)
Alliances (46779)
Alzheimer's disease (1205)
Antibody-drug conjugate (ADC) (62)
Approvals (16603)
Arizona (127)
Artificial intelligence (74)
Asia (40219)
Australia (6783)
Bankruptcy (296)
Best Places to Work (11423)
Biosimilars (70)
Biotechnology (153)
C2C Services and Suppliers (62596)
California (1552)
Canada (840)
Cancer (371)
Career advice (2560)
Cell therapy (115)
China (124)
Clinical research (64549)
Collaboration (120)
Colorado (65)
Connecticut (63)
COVID-19 (2701)
Cystic fibrosis (75)
Data (170)
Diabetes (79)
Diagnostics (5971)
Drug pricing (81)
Earnings (69455)
Employer resources (148)
Europe (89236)
Events (97075)
Executive appointments (112)
FDA (16864)
Florida (226)
Funding (105)
Gene therapy (93)
GLP-1 (592)
Government (4842)
Healthcare (19186)
Hotbed/Location (430699)
Illinois (247)
Indiana (123)
Infectious disease (2726)
Inflammatory bowel disease (93)
Interviews (547)
IPO (15805)
Job creations (3576)
Job search strategy (2139)
Kansas (91)
Layoffs (427)
Legal (7769)
Lung cancer (81)
Manufacturing (83)
Maryland (376)
Massachusetts (1297)
Medical device (12762)
Medtech (12765)
Mergers & acquisitions (16941)
Metabolic disorders (270)
Michigan (97)
Minnesota (205)
Neuroscience (1347)
New Jersey (488)
New York (500)
NextGen Class of 2024 (6787)
Non-profit (4849)
North Carolina (599)
Northern California (721)
Obesity (165)
Ohio (93)
Opinion (227)
Patents (69)
Pennsylvania (495)
People (50034)
Phase I (19764)
Phase II (28167)
Phase III (21495)
Pipeline (100)
Policy (61)
Postmarket research (3019)
Preclinical (8543)
Press Release (62)
Rare diseases (125)
Real estate (5474)
Recruiting (69)
Regulatory (23482)
Research institute (2561)
Resumes & cover letters (513)
South America (1259)
Southern California (637)
Startups (3409)
Texas (184)
United States (7430)
Vaccines (517)
Washington State (221)
Weight loss (157)
Date
Today (6)
Last 7 days (564)
Last 30 days (1986)
Last 365 days (37459)
2024 (25135)
2023 (40400)
2022 (51257)
2021 (55743)
2020 (54431)
2019 (48122)
2018 (36494)
2017 (32577)
2016 (31684)
2015 (36187)
2014 (28515)
2013 (24166)
2012 (25888)
2011 (26491)
2010 (24468)
652,998 Results for "national institute on drug abuse nida".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder
Gilgamesh Pharmaceuticals today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders.
March 14, 2024
·
3 min read
Bio NC
Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody
Cessation Therapeutics, Inc. today announced that it has been awarded an additional grant from the National Institute on Drug Abuse (NIDA, a division of the National Institutes of Health).
October 18, 2023
·
4 min read
Genetown
Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastogen for Substance Use Disorders
Delix Therapeutics today announced it has been awarded a $320,000 grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support the advancement of DLX-007.
December 13, 2023
·
5 min read
Biotech Bay
MAPS PBC Announces National Institute on Drug Abuse to Share Data for New Drug Application for MDMA-Assisted Therapy for Treatment of PTSD
MAPS Public Benefit Corporation (“MAPS PBC”) announced that the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health, has agreed to provide data to supplement the company’s new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for MDMA-assisted therapy as a treatment for post-traumatic stress disorder (“PTSD”).
June 21, 2023
·
5 min read
Drug Development
STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder
STALICLA SA, a clinical stage biotech advancing the first precision neurobiology platform (DEPI) for patients with neurodevelopmental and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH).
March 8, 2023
·
3 min read
Press Releases
Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network
September 4, 2024
·
2 min read
Pharm Country
BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) today announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder (OUD).
November 6, 2023
·
11 min read
BioCapital
Westat Awarded Contract to Continue Supporting the PATH Study
The National Institutes of Health’s (NIH’s) National Institute on Drug Abuse (NIDA) and the U.S. Food and Drug Administration’s (FDA’s) Center for Tobacco Products (CTP) have announced the award of a third contract to Westat to continue to support the Population Assessment of Tobacco and Health (PATH) Study.
February 21, 2024
·
3 min read
Pharm Country
Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH’s National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder
Tris Pharma, Inc. announced that the company has been awarded a grant expected to provide up to $16.6M over five years from the National Institute on Drug Abuse, part of the National Institutes of Health.
August 28, 2023
·
4 min read
Business
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD).
April 10, 2023
·
6 min read
1 of 65,300
Next